Narrow search
Showing 1 - 10 of 501
Cover Image
Patents and the Global Diffusion of New Drugs
Cockburn, Iain M.; Lanjouw, Jean O.; Schankerman, Mark - National Bureau of Economic Research (NBER) - 2014
This paper studies how patent rights and price regulation affect how fast new drugs are launched in different countries, using newly constructed data on launches of 642 new drugs in 76 countries for the period 1983-2002, and information on the duration and content of patent and price control...
Persistent link: https://www.econbiz.de/10010950846
Cover Image
Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007
Conti, Rena M.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 2014
We examine the impact of loss of U.S. patent exclusivity (LOE) on the prices and utilization of specialty drugs between 2001 and 2007. We limit our empirical cohort to drugs commonly used to treat cancer and base our analyses on nationally representative data from IMS Health. We begin by...
Persistent link: https://www.econbiz.de/10010950850
Cover Image
Direct to Consumer Advertising of Pharmaceutical Drugs: Information and Persuasion
Bar, Talia; Lillard, Dean R. - National Bureau of Economic Research (NBER) - 2014
We formally model direct to consumer advertising (DTCA) of prescription drugs and examine factors that determine a pharmaceutical firm's DTCA strategy. We highlight how the profitability of DTCA varies with the characteristics of the condition that the advertised drug treats, the incidence of...
Persistent link: https://www.econbiz.de/10010951290
Cover Image
Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process
Philipson, Tomas; Berndt, Ernst R.; Gottschalk, Adrian H. B. - National Bureau of Economic Research (NBER) - 2004
Congress enacted and renewed the Prescription Drug User Fee Acts (PDUFA) in 1992, and renewed it in 1997 and 2002, mandating FDA performance goals in reviewing and acting on drug applications within specified time periods. In turn, the FDA was permitted to levy user fees on drug sponsors...
Persistent link: https://www.econbiz.de/10005084928
Cover Image
Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?
Trusheim, Mark; Aitken, Murray L.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 2010
Much has been written about the seemingly less formal, more agile biotechnology industry and its extensive interactions with academia and startups, as well as its distinct scientific, manufacturing and regulatory profile. Employing a data base encompassing all 96 biologics and 212 small...
Persistent link: https://www.econbiz.de/10008635919
Cover Image
Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets
Danzon, Patricia M.; Furukawa, Michael F. - National Bureau of Economic Research (NBER) - 2011
This paper examines the role of regulation and competition in generic markets. Generics offer large potential savings … prompt entry, aggressive price competition and patient switching to generics. Key features are that pharmacists are … authorized and incentivized to switch patients to cheap generics. By contrast, in many other high and middle income countries …
Persistent link: https://www.econbiz.de/10009207072
Cover Image
The Effect of Drug Vintage on Survival: Micro Evidence from Puerto Rico's Medicaid Program
Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2004
Using micro data on virtually all of the drugs and diseases of over 500,000 people enrolled in Puerto Rico's Medicaid program, we examine the impact of the vintage (original FDA approval year) of drugs used to treat a patient on the patient's 3-year probability of survival, controlling for...
Persistent link: https://www.econbiz.de/10005718010
Cover Image
Pricing and Reimbursement in U.S. Pharmaceutical Markets
Berndt, Ernst R.; Newhouse, Joseph P. - National Bureau of Economic Research (NBER) - 2010
and on utilization. With this as background, we summarize major long-term trends in copayments and coinsurance rates for …
Persistent link: https://www.econbiz.de/10008531891
Cover Image
Financial Risk in the Biotechnology Industry
Golec, Joseph H.; Vernon, John A. - National Bureau of Economic Research (NBER) - 2007
The biotechnology industry has been an engine of innovation for the U.S. healthcare system and, more generally, the U.S. economy. It is by far the most research intensive industry in the U.S. In our analyses in the current paper, for example, we find that, over the past 25 years, average R&D...
Persistent link: https://www.econbiz.de/10005050410
Cover Image
Effects of Regulation on Drug Launch and Pricing in Interdependent Markets
Danzon, Patricia M.; Epstein, Andrew J. - National Bureau of Economic Research (NBER) - 2008
This study examines the effect of price regulation and competition on launch timing and pricing of new drugs. Our data cover launch experience in 15 countries for drugs in 12 therapeutic classes that experienced significant innovation over the decade 1992-2003. We use prices of established...
Persistent link: https://www.econbiz.de/10005575380